Literature DB >> 26631831

NICE restructures the Cancer Drugs Fund.

Talha Khan Burki.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26631831     DOI： 10.1016/S1470-2045(15)00549-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kojiro Shimozuma; Mitsuko Mouri; Yasuhiro Hagiwara; Takuya Kawahara; Shozo Ohsumi; Yasuo Hozumi; Yoshiaki Sagara; Yasuo Ohashi; Hirofumi Mukai
Journal:  BMC Cancer       Date:  2017-11-17       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.